SAB BIO to Participate in Upcoming Investor Conferences
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing SAB-142, has announced its participation in two upcoming investor conferences. The company, which focuses on a novel immunotherapy platform for potentially delaying type 1 diabetes onset or progression, will be present at:
1. The Guggenheim SMID Cap Biotech Conference on February 6, 2025, featuring a fireside chat from 2:00 – 2:25pm ET
2. The Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, delivering a company presentation from 10:00 – 10:30am ET
Both events will be accessible via live webcasts and archived recordings through the company's investor relations website.
SAB BIO (Nasdaq: SABS), una compagnia biofarmaceutica in fase clinica che sviluppa SAB-142, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda, che si concentra su una piattaforma innovativa di immunoterapia per potenzialmente ritardare l'insorgenza o la progressione del diabete di tipo 1, sarà presente a:
1. La Guggenheim SMID Cap Biotech Conference il 6 febbraio 2025, con una conversazione informale dalle 14:00 alle 14:25 ET
2. La Oppenheimer 35th Annual Healthcare Life Sciences Conference il 12 febbraio 2025, con una presentazione aziendale dalle 10:00 alle 10:30 ET
Entrambi gli eventi saranno accessibili tramite webcast dal vivo e registrazioni archiviate attraverso il sito web delle relazioni con gli investitori dell'azienda.
SAB BIO (Nasdaq: SABS), una empresa biofarmacéutica en etapa clínica que desarrolla SAB-142, ha anunciado su participación en dos próximas conferencias para inversores. La compañía, que se enfoca en una plataforma innovadora de inmunoterapia para potencialmente retrasar la aparición o progresión de la diabetes tipo 1, estará presente en:
1. La Guggenheim SMID Cap Biotech Conference el 6 de febrero de 2025, con una charla informal de 2:00 a 2:25 p.m. ET
2. La Oppenheimer 35th Annual Healthcare Life Sciences Conference el 12 de febrero de 2025, con una presentación de la compañía de 10:00 a 10:30 a.m. ET
Ambos eventos serán accesibles a través de transmisiones en vivo y grabaciones archivadas en el sitio web de relaciones con inversores de la empresa.
SAB BIO (Nasdaq: SABS), 임상 단계의 생명공학 회사로 SAB-142를 개발 중인 이 회사는 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 제1형 당뇨병의 발병 또는 진행을 잠재적으로 지연시키기 위한 새로운 면역 요법 플랫폼에 주력하는 이 회사는 다음 회의에 참석할 예정입니다:
1. 구겐하임 SMID Cap 생명공학 회의가 2025년 2월 6일에 열리며, 14:00 - 14:25 ET에 자유로운 대화가 진행됩니다.
2. 오펜하이머 제35회 연례 의료 생명 과학 회의가 2025년 2월 12일에 개최되며, 10:00 - 10:30 ET에 회사 발표가 진행됩니다.
두 행사 모두 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트 및 보관된 녹음으로 접근할 수 있습니다.
SAB BIO (Nasdaq: SABS), une entreprise biopharmaceutique en phase clinique développant SAB-142, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise, qui se concentre sur une nouvelle plateforme d'immunothérapie pour potentiellement retarder l'apparition ou la progression du diabète de type 1, sera présente à :
1. La Guggenheim SMID Cap Biotech Conference le 6 février 2025, avec une discussion informelle de 14h00 à 14h25 ET
2. La Oppenheimer 35th Annual Healthcare Life Sciences Conference le 12 février 2025, proposant une présentation de l'entreprise de 10h00 à 10h30 ET
Les deux événements seront accessibles par le biais de webcasts en direct et d'enregistrements archivés sur le site web des relations avec les investisseurs de l'entreprise.
SAB BIO (Nasdaq: SABS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das SAB-142 entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen, das sich auf eine neuartige Immuntherapie-Plattform konzentriert, um möglicherweise den Ausbruch oder Fortschritt von Typ-1-Diabetes zu verzögern, wird an folgenden Veranstaltungen teilnehmen:
1. Die Guggenheim SMID Cap Biotech Conference am 6. Februar 2025, mit einem informellen Gespräch von 14:00 bis 14:25 Uhr ET
2. Die Oppenheimer 35th Annual Healthcare Life Sciences Conference am 12. Februar 2025, mit einer Unternehmenspräsentation von 10:00 bis 10:30 Uhr ET
Beide Veranstaltungen sind über Live-Webcasts und archivierte Aufzeichnungen über die Investor Relations-Website des Unternehmens zugänglich.
- None.
- None.
MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim SMID Cap Biotech Conference
Date: February 6, 2025
Fireside Chat: 2:00 – 2:25pm ET
Webcast Link: https://wsw.com/webcast/guggen2/sabs/1999239
Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: February 12, 2025
Company Presentation: 10:00 – 10:30am ET
Webcast Link: https://wsw.com/webcast/oppenheimer39/sabs/2773928
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events” tab on the investor relations section of the SAB BIO website at https://ir.sab.bio/news-events/events.
About SAB BIO
SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: https://www.SAB.bio/ and follow SAB on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the data, development, clinical results, and efficacy of our T1D program and other discovery programs.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:
Kaelan Hollon
Vice President of Communications
khollon@sab.bio
Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
When is SAB BIO (SABS) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
What time is SAB BIO's presentation at the Oppenheimer Healthcare Conference 2025?
What is SAB BIO's main product in development?
How can investors access SAB BIO's conference presentations?
